Extending the Reach of Genetic Medicine Through Next-Generation Parvovirus Vector Technology
Time: 11:30 am
day: Day 1- Translation 1
Details:
• A comparison of LNPs and AAVs reveals key differences in immunogenicity and toxicity, suggesting potential benefits of combined use
• Improved targeting and uptake strategies aim to mitigate immune responses and toxicity in metabolic liver diseases
• Overcoming delivery challenges, for LNPs to be optimized for more effective transport of therapies to liver cells
